Faruqi & Faruqi Reminds GeneDx Investors of August 3 Lead Plaintiff Deadline

Regulation
โดย GlobeNewswire·Read original
Summary · why it matters

Faruqi & Faruqi, LLP reminds investors in GeneDx Holdings Corp. that the deadline to seek lead plaintiff appointment in a federal securities class action is August 3, 2026. The lawsuit alleges the company and its executives made false or misleading statements about the importance of the Fabric Genomics acquisition, the durability of average reimbursement rates, and the outlook for gross margins. On May 4, 2026, GeneDx reported first-quarter results that missed expectations, cut its 2026 revenue guidance from $540–$555 million to $475–$490 million, disclosed an average reimbursement rate of $3,300, and took a $31.3 million goodwill impairment charge on the Fabric Genomics acquisition it had purchased for $36.5 million a year earlier. The stock fell over 49%, or $33.42 per share, the following day. Investors who purchased or acquired GeneDx securities between April 16, 2025 and May 4, 2026 may contact the firm to discuss their legal rights.

Impact on stocks 1

Biotech & Genomic Medicine▼ · 1 stocks
GeneDx Holdings Corp.
WGS
▼ NegativeRegulationrelevance

Securities class action lawsuit alleging false statements about Fabric Genomics acquisition, reimbursement rates, and gross margins; stock fell 49% after Q1 miss and guidance cut.

Off-coverage companies 1

Fabric Genomics, Inc.Private▼ Negative
Capitalrelevance

Fabric Genomics acquisition resulted in $31.3 million goodwill impairment, indicating overpayment and poor performance.

© 2026 MarketDXNews